The PI3K Pathway As Drug Target in Human Cancer
Top Cited Papers
- 20 February 2010
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (6), 1075-1083
- https://doi.org/10.1200/jco.2009.25.3641
Abstract
The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metabolism. This pathway is activated by several different mechanisms in cancers, incl...Keywords
This publication has 109 references indexed in Scilit:
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human CancerCancer Cell, 2009
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Should individual PI3 kinase isoforms be targeted in cancer?Current Opinion in Cell Biology, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Slow Self-Activation Enhances The Potency of Viridin ProdrugsJournal of Medicinal Chemistry, 2008
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- Tenets of PTEN Tumor SuppressionCell, 2008
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997